Phase 2 N=94 Randomized Triple-blind Treatment

Toradol to Reduce Ureteroscopic Symptoms Trial

Urinary Lithiasis · Kidney Diseases · Kidney Stone · Pain, Postoperative

Bottom Line

View on ClinicalTrials.gov: NCT03111381 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2021

Primary outcome: Primary: Post-operative Pain — 22; 30 milligram morphine equivalent

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Toradol (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Yale University
Primary completion: Jun 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Post-operative Pain	22; 30	—
SECONDARY Number of Participants With Complications	6; 4	—

Summary

Double blinded randomized controlled clinical trial to assess the impact of intraoperative Toradol on post-operative pain scores for patients undergoing ureteroscopy for urinary stone management.

Eligibility Criteria

Inclusion Criteria

Undergoing Ureteroscopy for kidney stone management between age 18-80.

Exclusion Criteria

Unable to provide consent
Contraindications to Toradol

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03111381). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.